The RSI Indicator for SNPHF moved out of oversold territory on December 03, 2024. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 39 similar instances when the indicator left oversold territory. In of the 39 cases the stock moved higher. This puts the odds of a move higher at .
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Momentum Indicator moved above the 0 level on December 23, 2024. You may want to consider a long position or call options on SNPHF as a result. In of 62 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for SNPHF just turned positive on December 04, 2024. Looking at past instances where SNPHF's MACD turned positive, the stock continued to rise in of 36 cases over the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 179 cases where SNPHF Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
SNPHF moved below its 50-day moving average on November 15, 2024 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for SNPHF crossed bearishly below the 50-day moving average on November 19, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.511) is normal, around the industry mean (5.632). P/E Ratio (15.314) is within average values for comparable stocks, (48.974). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.004). Dividend Yield (0.027) settles around the average of (0.164) among similar stocks. P/S Ratio (1.667) is also within normal values, averaging (3.643).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. SNPHF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SNPHF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 76, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry PharmaceuticalsMajor